Discover
ENTA
Enanta Pharmaceuticals, Inc.
12.50
2 x 8.82
2 x 15.23
bid
ask
+
0.40
3.31%
2 @ 04:01 PM
12.50 +0.00 (0.00%)
| Ytd | -20.74% | |
| 1y | 9.08% |
12.07
day range
12.61
10.47
52 week range
16.85
| Open | 12.07 | Prev Close | 12.10 | Low | 12.07 | High | 12.61 | Mkt Cap | 364.07M |
| Vol | 182.07K | Avg Vol | 228.45K | EPS | -2.42 | P/E | N/A | Forward P/E | -1.32 |
| Beta | 0.57 | Short Ratio | 20.91 | Inst. Own | 100.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 13.07 | 200-d Avg | 13.45 | 1yr Est | 16.88 |
| Income Statement | |||
| Total Revenue | 14.36M | ||
| Revenues (USD) | 14.36M | ||
| Gross Profit | 14.36M | ||
| Operating Expenses | 31.60M | ||
| Research and Development Expense | 22.13M | ||
| Selling, General and Administrative Expense | 9.47M | ||
| Operating Income | -17.24M | ||
| Interest Expense | 4.13M | ||
| Income Tax Expense | 36.00K | ||
| Net Income | -19.50M | ||
| Net Income Common Stock | -19.50M | ||
| Net Income Common Stock (USD) | -19.50M | ||
| Consolidated Income | -19.50M | ||
| Earnings per Basic Share | -0.67 | ||
| Earnings per Basic Share (USD) | -0.67 | ||
| Earnings per Diluted Share | -0.67 | ||
| Earning Before Interest & Taxes (EBIT) | -15.33M | ||
| Earning Before Interest & Taxes (USD) | -15.33M | ||
| Weighted Average Shares | 29.09M | ||
| Weighted Average Shares Diluted | 29.09M | ||
| Balance Sheet | |||
| Cash and Equivalents | 33.42M | ||
| Cash and Equivalents (USD) | 33.42M | ||
| Investments | 181.43M | ||
| Investments Current | 156.09M | ||
| Investments Non-Current | 25.35M | ||
| Trade and Non-Trade Receivables | 6.53M | ||
| Current Assets | 203.62M | ||
| Property, Plant & Equipment Net | 67.79M | ||
| Total Assets | 296.87M | ||
| Debt Current | 3.91M | ||
| Total Debt | 55.66M | ||
| Current Liabilities | 54.17M | ||
| Debt Non-Current | 51.75M | ||
| Total Liabilities | 195.80M | ||
| Accumulated Retained Earnings (Deficit) | -449.46M | ||
| Accumulated Other Comprehensive Income | -927.00K | ||
| Shareholders Equity | 101.07M | ||
| Shareholders Equity (USD) | 101.07M | ||
| Assets Non-Current | 93.25M | ||
| Total Debt (USD) | 55.66M | ||
| Deferred Revenue | 125.07M | ||
| Liabilities Non-Current | 141.64M | ||
| Trade and Non-Trade Payables | 3.29M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.19M | ||
| Net Cash Flow from Financing | -5.54M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -1.51M | ||
| Capital Expenditure | -7.00K | ||
| Issuance (Purchase) of Equity Shares | 492.00K | ||
| Issuance (Repayment) of Debt Securities | -6.03M | ||
| Net Cash Flow from Investing | 14.01M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 14.01M | ||
| Net Cash Flow from Operations | -9.97M | ||
| Share Based Compensation | 3.68M | ||